Potential new therapeutic for Relapsing MS patients
Posted: Fri Feb 19, 2016 2:02 am
RADIANCE phase 2 trial of ozanimod, an investigational selective S1P 1 and 5 receptor modulators for relapsing multiple sclerosis (MS) patients results showed significant reductions in the cumulative number of total gadolinium-enhancing (GdE) lesions...Read more - http://www.ms-uk.org/MSnews